Regeneron Pharmaceuticals, Inc. $REGN Stock Purchased by Bessemer Group Inc.

Bessemer Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 56.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,445 shares of the biopharmaceutical company’s stock after buying an additional 881 shares during the quarter. Bessemer Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,853,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Hantz Financial Services Inc. grew its position in Regeneron Pharmaceuticals by 5.6% during the third quarter. Hantz Financial Services Inc. now owns 472 shares of the biopharmaceutical company’s stock valued at $358,000 after acquiring an additional 25 shares during the last quarter. Harbour Investments Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 14.6% in the 3rd quarter. Harbour Investments Inc. now owns 729 shares of the biopharmaceutical company’s stock valued at $553,000 after purchasing an additional 93 shares in the last quarter. Phoenix Financial Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 13.7% in the 3rd quarter. Phoenix Financial Ltd. now owns 1,261 shares of the biopharmaceutical company’s stock valued at $956,000 after purchasing an additional 152 shares in the last quarter. Diversified Trust Co grew its holdings in shares of Regeneron Pharmaceuticals by 7.8% during the 3rd quarter. Diversified Trust Co now owns 2,675 shares of the biopharmaceutical company’s stock valued at $2,028,000 after purchasing an additional 194 shares during the last quarter. Finally, Aberdeen Group plc grew its holdings in shares of Regeneron Pharmaceuticals by 560.7% during the 3rd quarter. Aberdeen Group plc now owns 671,042 shares of the biopharmaceutical company’s stock valued at $508,831,000 after purchasing an additional 569,476 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Wells Fargo & Company upped their price target on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the company an “equal weight” rating in a research report on Monday, November 2nd. Barclays raised their price objective on Regeneron Pharmaceuticals from $917.00 to $1,075.00 and gave the company an “overweight” rating in a research note on Tuesday, November 17th. Piper Sandler lifted their price objective on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a report on Monday, October 19th. Argus raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price for the company in a research note on Thursday, October 1st. Finally, Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the company an “equal weight” rating in a report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $904.41.

View Our Latest Stock Report on Regeneron Pharmaceuticals

Recent Regeneron Pharmaceuticals Headlines

These are some of the REGN headlines that stood out recently:

  • Positive Sentiment: The FDA approved Livsayis (cemdisiran) for adults with anti-AChR-positive generalized myasthenia gravis. It is the first approved siRNA therapy for the condition and the only treatment given by subcutaneous injection just four times a year. Phase 3 results showed sustained disease control between doses, giving Regeneron a new neurology product and potential revenue source. Livsayis FDA approval announcement
  • Neutral Sentiment: Director Andrew Murphy sold 5,011 shares under a pre-arranged Rule 10b5-1 plan. He retained 46,779 shares afterward, making the transaction a limited signal about his view of the company. Insider transaction report
  • Neutral Sentiment: Livsayis will compete with established treatments for generalized myasthenia gravis, so adoption and commercial performance remain important to watch despite its distinctive dosing schedule. Livsayis competitive context

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Christine Poon sold 7,830 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the transaction, the director directly owned 5,219 shares of the company’s stock, valued at approximately $5,057,680.71. The trade was a 60.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrew Murphy sold 5,011 shares of the firm’s stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $957.76, for a total transaction of $4,799,335.36. Following the completion of the sale, the insider directly owned 46,779 shares of the company’s stock, valued at approximately $44,803,055.04. This represents a 9.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 32,039 shares of company stock worth $29,825,285. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of REGN opened at $920.69 on Friday. The stock has a market capitalization of $95.25 billion, a P/E ratio of 20.33, a PEG ratio of 1.22 and a beta of 0.10. The company has a quick ratio of 2.89, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $829.76 and a two-hundred day simple moving average of $752.07. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company’s revenue for the quarter was up 36.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $11.83 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be issued a $0.94 dividend. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Recommended Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.